| All patients N = 159 | Potential Undertreatment N = 103 | According to guideline treatment N = 56 |
---|---|---|---|
ASA | 66 (41.5%) | 39 (37.9%) | 27 (48.2%) |
Warfarin | 53 (33.3%) | 1 (1.0%) | 52 (92.9%) |
Clopidogrel | 5 (3.1%) | 3 (2.9%) | 2 (3.6%) |
Digoxin | 74 (46.5%) | 43 (41.7%) | 30 (53.6%) |
Atenolol | 58 (36.5%) | 29 (28.2%) | 29 (51.8%) |
Metoprolol | 17 (10.7%) | 8 (7.8%) | 9 (16.1%) |
Carvedilol | 2 (1.3%) | 2 (1.9%) | 0 (0%) |
Propranolol | 10 (6.3%) | 8 (7.8%) | 2 (3.6%) |
Simvastatin | 21 (13.2%) | 12 (11.7%) | 9 (16.1%) |
Atorvastatin | 20 (12.6%) | 10 (9.7%) | 10 (17.9%) |
Captopril | 1 (0.6%) | 0 (0%) | 1 (1.8%) |
Enalapril | 33 (20.8%) | 17 (16.5%) | 16 (28.6%) |
Furosemide | 89 (56.0%) | 53 (51.5%) | 36 (64.3%) |
Spironolactone | 72 (45.3%) | 43 (41.7%) | 29 (51.8%) |
Hydrochlorothiazide | 14 (8.8%) | 9 (8.7%) | 5 (8.9%) |
Nifedipine/amlodipine | 3 (1.9%) | 2 (1.9%) | 1 (1.8%) |
Monthly benzathine penicillin | 17 (10.7%) | 3 (2.9%) | 14 (25.0%) |
PTU | 19 (11.9%) | 12 (11.7%) | 7 (12.5%) |